JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Development and validation of risk-stratified biopsy decision pathways incorporating MRI and PSA-derived indicators

  • 0Department of Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Annals of Medicine +

|

January 1, 2025

|

January 1, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Developing risk-adapted pathways using MRI, prostate-specific antigen density (PSAD), and free to total PSA (f/tPSA) improves clinically significant prostate cancer (csPCa) detection while reducing unnecessary biopsies.

Area Of Science

  • Urology
  • Radiology
  • Oncology

Background

  • Prostate cancer diagnosis relies on accurate risk stratification to balance detection of clinically significant disease with avoidance of unnecessary procedures.
  • Magnetic Resonance Imaging (MRI) and prostate-specific antigen (PSA) markers like PSA density (PSAD) and free to total PSA ratio (f/tPSA) are key tools in this assessment.

Purpose Of The Study

  • To develop and evaluate risk-adapted conditional biopsy pathways integrating MRI, PSAD, and f/tPSA for enhanced detection of clinically significant prostate cancer (csPCa).
  • To minimize the rate of 'negative' biopsies in patients with low-risk profiles.

Main Methods

  • Retrospective analysis of 1018 patients' data including PI-RADS category, PSAD, f/tPSA, and biopsy-pathology.
  • Construction of risk stratification matrix tables combining MRI findings with PSA-derived indicators.
  • Establishment of six biopsy decision pathways (three clinical, three MRI-combined) and assessment of csPCa detection, biopsy avoidance, and negative biopsy rates.
  • Evaluation of pathway net benefit using Decision Curve Analysis (DCA).

Main Results

  • MRI-combined pathways demonstrated higher csPCa detection rates (94%-96%) compared to clinical pathways (85%-91%).
  • The 'MRI + PSAD + f/tPSA' pathway achieved a 94% csPCa detection rate with 40% biopsy avoidance and 25% negative biopsy rate.
  • Decision Curve Analysis confirmed significantly higher net benefits for MRI-combined pathways.

Conclusions

  • Integrating MRI with PSA-derived indicators (PSAD, f/tPSA) provides effective risk stratification for prostate cancer management.
  • These integrated pathways enhance csPCa detection and significantly reduce unnecessary 'negative' biopsies, improving patient outcomes.

Keywords: